Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intron A for Hypertrophic Scar
NCT00686478Phase 3
Key facts
- Status
- Withdrawn
- Countries
- 1
- Sponsor
- University of Alberta
- Modality
- Cytokines & Interferons
- Drugs
- interferon alfa
- Conditions
- Hypertrophic Scar (HS)
01
Overview
Phase 3, randomised, double-blind trial in Hypertrophic Scar (HS) comparing Intron A with Placebo (2 arms). Primary endpoint: Systemic effect of Intron A on hypertrophic scar. Status: withdrawn.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Intron A
1 million IU daily x 7 days, then 3 million IU 3x/week SC
Placebo
Placebo SC matching Intron A schedule
03
Who it enrols
Burn patients with > 5% TBSA and hypertrophic scars, excluding those with cardiac/CNS disorders, autoimmune disease, immunodeficiency, or organ dysfunction.
04
Endpoints
Primary
Systemic effect of Intron A on hypertrophic scar
Beyond the preview
Go deeper on NCT00686478.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686478.